MicroRNA Biomarkers & Therapeutics Market
完整報告名稱與涵蓋範圍
MicroRNA Biomarkers & Therapeutics Market Size, Share & Trends Analysis Report, By Product Type (MicroRNA Diagnostic and Prognostic Assays, MicroRNA Therapeutics (Mimics and Antagomirs), Research Tools and Profiling Services), By Application (Oncology, Cardiovascular Disease, Neurological Disorders, Infectious, Liver and Other Diseases), By Technology (qPCR and Microarray Profiling, Next-Generation Sequencing, Oligonucleotide Delivery Platforms), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The microRNA biomarkers and therapeutics market covers diagnostic and prognostic assays based on circulating or tissue microRNA signatures, therapeutics that mimic or inhibit specific microRNAs, and the research tools and profiling services that support discovery. General oligonucleotide therapeutics such as antisense and siRNA drugs directed at messenger RNA are addressed in a separate InsightAce study and excluded here. Diagnostic and research revenue is established; therapeutic revenue depends on clinical progression and is forecast accordingly.
Diagnostic momentum comes from the stability of microRNAs in blood and other fluids, which enables minimally invasive tests for early cancer detection, cardiovascular risk and neurological disease, and from sequencing and PCR platforms that make multi-marker panels reproducible at clinical scale. On the therapeutic side, anti-miR candidates for kidney and liver disease and tumor-targeted mimics have reached mid-stage trials after early setbacks taught the field about delivery and off-target effects, and the acquisition of a leading anti-miR developer by a large pharmaceutical company has renewed commercial interest. Standardisation of pre-analytical handling and regulatory frameworks for multi-analyte signatures shape diagnostic adoption.
North America, Europe and Japan lead in assay commercialisation and therapeutic development, with China increasing research output. Competition involves specialist microRNA diagnostic companies, oligonucleotide drug developers and life science tool providers.
The InsightAce study includes revenue forecasts in US$ for all product type, application, technology and end user and regional segments across 2026-2035, segment-level trend analysis, competitive positioning assessment and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global MicroRNA Biomarkers & Therapeutics Market Snapshot
Chapter 4. Global MicroRNA Biomarkers & Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. Product Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product Type:
5.2.1. MicroRNA Diagnostic and Prognostic Assays
5.2.2. MicroRNA Therapeutics (Mimics and Antagomirs)
5.2.3. Research Tools and Profiling Services
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. Application & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
6.2.1. Oncology
6.2.2. Cardiovascular Disease
6.2.3. Neurological Disorders
6.2.4. Infectious, Liver and Other Diseases
Chapter 7. Market Segmentation 3: By Technology Estimates & Trend Analysis
7.1. Technology & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Technology:
7.2.1. qPCR and Microarray Profiling
7.2.2. Next-Generation Sequencing
7.2.3. Oligonucleotide Delivery Platforms
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Diagnostic Laboratories
8.2.2. Pharmaceutical and Biotechnology Companies
8.2.3. Academic and Research Institutes
Chapter 9. MicroRNA Biomarkers & Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Hummingbird Diagnostics GmbH
11.2. DiamiR Biosciences Corp.
11.3. Regulus Therapeutics (Novartis AG)
11.4. TransCode Therapeutics, Inc.
11.5. Toray Industries, Inc.
11.6. QIAGEN N.V.
11.7. Thermo Fisher Scientific Inc.
11.8. Bio-Rad Laboratories, Inc.
11.9. Sirnaomics Ltd.
11.10. MiNA Therapeutics Limited
11.11. Ionis Pharmaceuticals, Inc.
11.12. Abcam plc (Danaher)
11.13. Mercodia AB
11.14. Cosmo Bio Co., Ltd.
11.15. Interpace Biosciences, Inc.
圖表清單 List of Tables & Figures
Table 1. Global MicroRNA Biomarkers & Therapeutics Market Revenue Forecast by Product Type, 2026-2035 (US$ Mn)
Figure 1. Global MicroRNA Biomarkers & Therapeutics Market Segmentation and Scope Overview
Table 2. Global MicroRNA Biomarkers & Therapeutics Market Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 2. Global MicroRNA Biomarkers & Therapeutics Market Share by Product Type, 2026 & 2035
Table 3. Global MicroRNA Biomarkers & Therapeutics Market Revenue Forecast by Technology, 2026-2035 (US$ Mn)
Figure 3. MicroRNA Diagnostic Assays by Disease Area and Regulatory Status
Table 4. Global MicroRNA Biomarkers & Therapeutics Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Anti-miR and miRNA Mimic Therapeutic Pipeline by Phase and Delivery Approach
Table 5. Global MicroRNA Biomarkers & Therapeutics Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific MicroRNA Biomarkers & Therapeutics Growth Opportunity Analysis
Table 6. North America MicroRNA Biomarkers & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key MicroRNA Biomarkers & Therapeutics Market Participants
Table 7. Europe MicroRNA Biomarkers & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global MicroRNA Biomarkers & Therapeutics Market
Table 8. Asia Pacific MicroRNA Biomarkers & Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Circulating MicroRNA Sample Handling and Standardisation Requirements
Table 9. Strategic Developments of Leading MicroRNA Biomarkers & Therapeutics Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們